Company Vical Incorporated Nasdaq
Equities
US9256022032
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Prescription Therapeutics
100.0
%
| 7 | 100.0 % | 8 | 100.0 % | +15.31% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 7 | 100.0 % | 8 | 100.0 % | +15.31% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Albert Marchio
CEO | Chief Executive Officer | 72 | 30/11/20 |
Nancy Seretta
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/15 |
Aaron Fox-Collis
AUD | Comptroller/Controller/Auditor | - | 30/06/20 |
Aron Aizenstat
PRN | Corporate Officer/Principal | - | - |
Sue Fattor
HRO | Human Resources Officer | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Albert Marchio
CEO | Chief Executive Officer | 72 | 30/11/20 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 5,973,306 | 5,877,545 ( 98.40 %) | 0 | 98.40 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+2.97% | 108B | |
+10.21% | 105B | |
+1.57% | 23.46B | |
-12.77% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.50% | 17.19B | |
+6.00% | 13.99B | |
+37.20% | 12.53B |